Aporte a la rutina de la trinchera asistencial donde los conocimientos se funden con las demandas de los pacientes, sus necesidades y las esperanzas de permanecer en la gracia de la SALUD.
jueves, 25 de marzo de 2010
Recently Updated Advisory Committee Materials
Recently Updated Advisory Committee Materials
Posted on March 25, 2010
º Oncologic Drugs Advisory Committee
^ 2010 Meeting Materials, Oncologic Drugs Advisory Committee1
^ CGPI Backup Presentation, Omacetaxine (Omapro), for the March 22, 2010 Meeting of the Oncologic Drugs Advisory Committee (PDF – 59.6KB)2 (PDF - 60KB)
^ Final Agenda for the March 22, 2010 Meeting of the Oncologic Drugs Advisory Committee3 (PDF - 52KB)
^ Final Meeting Roster for the March 22, 2010 Meeting of the Oncologic Drugs Advisory Committee4 (PDF - 24KB)
^ FDA Core Presentation, Omacetaxine (Omapro), for the March 22, 2010 Meeting of the Oncologic Drugs Advisory Committee (PDF – 553KB)5 (PDF - 554KB)
^ Slides for the March 22, 2010 Meeting of the Oncologic Drugs Advisory Committee6
^ Final Questions for the March 22, 2010 Meeting of the Oncologic Drugs Advisory Committee-PM Session-ChemGenex-Omapro7 (PDF - 23KB)
^ FDA Core Presentation, Pixuvri (Pixantrone), for the March 22, 2010 Meeting of the Oncologic Drugs Advisory Committee (PDF – 482KB)8 (PDF - 482KB)
^ CTI Backup Presentation, Pixuvri (Pixantrone), for the March 22, 2010 Meeting of the Oncologic Drugs Advisory Committee (PDF – 1.13MB)9 (PDF - 1167KB)
^ CTI Core Presentation, Pixuvri (Pixantrone), for the March 22, 2010 Meeting of the Oncologic Drugs Advisory Committee (PDF – 720KB)10 (PDF - 721KB)
^ Final Questions for the March 22, 2010 Meeting of the Oncologic Drugs Advisory Committee-AM Session-Cell Therapeutics-Pixantrone11 (PDF - 59KB)
^ CGPI Core Presentation, Omacetaxine (Omapro), for the March 22, 2010 Meeting of the Oncologic Drugs Advisory Committee (PDF – 1.01MB)12 (PDF - 1036KB)
and much more to see:
http://www.fda.gov/AdvisoryCommittees/WhatsNew/default.htm
No hay comentarios:
Publicar un comentario